The utilization of CTCs as a tumor malignancy indicator can improve patient care with a comprehensive isolation device. However, capturing CTCs has halted progress due to poor translational results. This presentation details a system achieving sensitive CTC capture through dendrimer-mediated binding, biomimetic cell rolling, and antibody cocktails. Nano-engineered dendrimers with functionalized antibodies lower off-rate, increasing capture sensitivity. The antibody cocktail outperforms EpCAM-based approach through active targeting of CA9, EGFR, and c-MET. Cell rolling improves cancer cell detection by reducing velocity in fluidic channels. These strategies enable CTC detection from patients' samples with higher sensitivity than EpCAM-based approach.